Short description
Viamet discovers and develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases.
Description
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Last funding
Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Morrisville, North Carolina, United States, North America
Founded on
January 1, 2005
Closed on
January 1, 2018
Exited on
January 3, 2018
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, Noaccessforu, Blurry Noaccess, No Way, Noaccess, Blurry Noaccess, Noway Youcantaccess
Sign in for full access
Founders
Holden Thorp, Robert Schotzinger